Summary
BeiGene, Ltd. (ONC) has filed an 8-K report detailing two significant developments. Firstly, the company announced on July 17, 2020, that the China National Medical Products Administration's Center for Drug Evaluation (CDE) has accepted a New Drug Application (NDA) for pamiparib, an investigational PARP1 and PARP2 inhibitor. This NDA is for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer with specific BRCA mutations in patients who have undergone prior chemotherapy. Secondly, on July 20, 2020, BeiGene entered into a collaboration agreement with Assembly Biosciences, Inc. This partnership focuses on Assembly's portfolio of three clinical-stage core inhibitor candidates for the treatment of chronic hepatitis B virus (HBV) infection, specifically within the China market. These developments highlight BeiGene's progress in advancing its oncology pipeline and expanding its therapeutic focus into infectious diseases through strategic partnerships.
Key Highlights
- 1Acceptance of NDA for pamiparib by China's CDE for BRCA-mutated advanced ovarian cancer.
- 2Pamiparib targets PARP1 and PARP2, indicating progress in precision oncology.
- 3Collaboration with Assembly Biosciences for chronic HBV treatment candidates in China.
- 4The collaboration includes three clinical-stage core inhibitor candidates for HBV.
- 5These events signal significant pipeline advancements for BeiGene in both oncology and infectious diseases.
- 6The filings include press releases detailing these key announcements.